Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Glucagon, a hormone involved in regulating appetite, loses its ability to help obese people feel full after a meal, but it continues to suppress hunger pangs in people with type 1 diabetes, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
The primary role of glucagon, a hormone secreted by the pancreas, is to signal the body to release stored glucose when blood sugar falls too low. But growing evidence suggests the hormone also may play a role in controlling food intake and feelings of fullness, or satiation, through signaling the body to reduce levels of other appetite hormones like ghrelin.
"Once a person becomes obese, glucagon no longer induces feelings of fullness," said the study's lead author, Ayman M. Arafat, MD, of Charité-University Medicine in Berlin, Germany. "Further research is needed to determine why glucagon no longer suppresses appetite effectively in this population, even though they are otherwise healthy."
The prospective, double-blinded, placebo-controlled study investigated glucagon levels and appetite among 11 obese people, 13 people with type 1 diabetes and 13 lean people. Participants received injections of either glucagon or a placebo. Researchers then measured participants' appetites using a satiety scale as well as levels of the appetite hormone ghrelin.
Feelings of fullness did not differ between obese study participants who received glucagon injections and those who were given the placebo. In comparison, participants who were lean or had type 1 diabetes reported feeling significantly more full after receiving glucagon. The response to the hormone was detectable in this population, even 24 hours after it was administered.
"The findings could influence efforts to develop new treatments for obesity and diabetes," Arafat said. "Although therapeutic agents that influence glucagon and other hormones currently are considered a promising avenue for research, this study suggests a treatment involving glucagon may be ineffective in controlling meal size in people who are obese."
Other researchers working on the study include: M. Weickert of University of Warwick; A. Adamidou, F. Perschel, J. Spranger, M. Möhlig and A. Pfeiffer of Charité-University Medicine; and B. Otto of Klinikum der Universität München.
The article, "The Impact of Insulin-independent Glucagon-induced Suppression of Total-Ghrelin on Satiety in Obesity and Type 1 Diabetes Mellitus," was published online Aug. 20.
The Role of Insulin-Like Growth Factor (IGF) Binding Protein-2 in the Insulin-Mediated Decrease in IGF-I Bioactivity;October 21, 2009, doi: 10.1210/jc.2009-0875
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Society, The Endocrine. "Problems with appetite hormone found in people with both diabetes and obesity." Medical News Today. MediLexicon, Intl., 22 Aug. 2013. Web.
5 Dec. 2013. <http://www.medicalnewstoday.com/releases/265079>
Society, T. (2013, August 22). "Problems with appetite hormone found in people with both diabetes and obesity." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265079.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.